RBC Capital analyst, Randall Stanicky, noted that this morning, INSYS Therapeutics (NASDAQ: INSY) announced that it has received approval for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE